Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.

Two different enzyme preparations, agalsidase alfa (Replagal(TM), Shire) and beta (Fabrazyme(TM), Genzyme), are registered for treatment of Fabry disease. We compared the efficacy of and tolerability towards the two agalsidase preparations administered at identical protein dose in a randomized contr...

Full description

Bibliographic Details
Main Authors: Anouk C Vedder, Gabor E Linthorst, Gunnar Houge, Johannna E M Groener, Els E Ormel, Berto J Bouma, Johannes M F G Aerts, Asle Hirth, Carla E M Hollak
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2007-07-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC1913555?pdf=render

Internet

http://europepmc.org/articles/PMC1913555?pdf=render

Similar Items